Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
Oculis Wins FDA IND Clearance For Privosegtor In Acute MS Relapses, Including Optic Neuritis And Ambulatory Relapses, With Primary Endpoint As Early As Three Months
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Wall Street Analysts Think Oculis Holding AG (OCS) Could Surge 384.89%: Read This Before Placing a Bet
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
Down 21.1% in 4 Weeks, Here's Why Oculis Holding AG (OCS) Looks Ripe for a Turnaround
Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $40
Oculis Holding AG (NASDAQ:OCS) Q3 Loss Narrows as Year-End Clinical Catalysts Near
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
Oculis Holding Q3 EPS $(0.37) Beats $(0.49) Estimate, Sales $8.619K Miss $290.000K Estimate
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.